The GAD-7 (Generalized Anxiety Disorder 7-item scale) is the standard brief screener for generalized anxiety disorder — and, like the PHQ-9 for depression, it doubles as a severity tracker during treatment. Seven items, a 0–21 total score, and validated severity bands make it the go-to anxiety measure in primary care and behavioral health.
Quick answer: The GAD-7 is a validated 7-item anxiety screener scored 0–21. Severity bands: 0–4 minimal, 5–9 mild, 10–14 moderate, 15–21 severe. A score ≥10 is the positive-screen cutoff for generalized anxiety disorder. It is routinely paired with the PHQ-9 depression screener in measurement-based care.
Interactive Screening Calculator
PHQ-9 · GAD-7 · PHQ-2 — live scoring, no signup
PHQ-9 — Depression (9 items, 0–27)
1. Little interest or pleasure in doing things
2. Feeling down, depressed, or hopeless
3. Trouble falling or staying asleep, or sleeping too much
4. Feeling tired or having little energy
5. Poor appetite or overeating
6. Feeling bad about yourself — or that you are a failure or have let yourself or your family down
7. Trouble concentrating on things
8. Moving or speaking so slowly others noticed, or being so fidgety/restless you have been moving around a lot more than usual
9. Thoughts that you would be better off dead, or of hurting yourself in some way
0/9 answered
GAD-7 — Anxiety (7 items, 0–21)
1. Little interest or pleasure in doing things
2. Feeling down, depressed, or hopeless
3. Trouble falling or staying asleep, or sleeping too much
4. Feeling tired or having little energy
5. Poor appetite or overeating
6. Feeling bad about yourself — or that you are a failure or have let yourself or your family down
7. Trouble concentrating on things
0/7 answered
PHQ-9 Total
0/27Suggested ICD-10-CM if criteria met: F32.9/F33.9 · CPT 96127 billable when staff-administered & scored
GAD-7 Total
0/21Suggested ICD-10-CM if criteria met: F41.1 · CPT 96127 billable when staff-administered & scored
Educational tool — not a diagnosis. Results require interpretation by a qualified clinician. This screen does not replace the DSM-5-TR clinical interview.
This guide covers scoring, interpretation, and the clinical workflow around the GAD-7.
Background: How the GAD-7 Was Developed and Validated
The GAD-7 was developed by Spitzer, Kroenke, Williams, and Löwe and validated in a 2006 study published in Archives of Internal Medicine across roughly 2,740 primary care patients. It was derived from the anxiety module of the PRIME-MD diagnostic interview — distilled into a 7-item self-report that takes about 2 minutes to complete.
At the ≥10 cutoff, the GAD-7 achieves roughly 89% sensitivity and 82% specificity for generalized anxiety disorder, and it performs well as a broad screen for any anxiety disorder — elevated scores also appear in panic disorder, social anxiety disorder, and PTSD. The instrument is free to use in clinical practice and is available in multiple validated translations.
The GAD-7 was designed as the anxiety counterpart to the PHQ-9 depression screener — same research group, same 0–3 response scale, same "past 2 weeks" frame. Administering both takes under 5 minutes and covers the two most common behavioral health presentations.
The 7 Items
Each item asks about symptoms over the past 2 weeks. Response options are identical for all items:
| Response | Points |
|---|---|
| Not at all | 0 |
| Several days | 1 |
| More than half the days | 2 |
| Nearly every day | 3 |
| # | Item (abbreviated) |
|---|---|
| 1 | Feeling nervous, anxious, or on edge |
| 2 | Not being able to stop or control worrying |
| 3 | Worrying too much about different things |
| 4 | Trouble relaxing |
| 5 | Being so restless that it is hard to sit still |
| 6 | Becoming easily annoyed or irritable |
| 7 | Feeling afraid as if something awful might happen |
Scoring
Sum all seven item scores. Total range: 0–21.
| Step | Calculation |
|---|---|
| Item scores | Each item: 0, 1, 2, or 3 |
| Total score | Sum of items 1–7 |
| Possible range | 0 (no anxiety symptoms) to 21 (all symptoms nearly every day) |
Severity Bands
The GAD-7 total maps to four severity categories:
| Total score | Severity | Clinical meaning |
|---|---|---|
| 0–4 | Minimal anxiety | Few or no symptoms; routine care |
| 5–9 | Mild anxiety | Subthreshold or mild symptoms; watchful waiting, lifestyle measures, rescreen |
| 10–14 | Moderate anxiety | Positive screen for generalized anxiety disorder; treatment recommended |
| 15–21 | Severe anxiety | Active treatment indicated — therapy, medication, or both |
The ≥10 Cutoff — What It Means
A GAD-7 score of 10 or higher is the validated positive-screen threshold for generalized anxiety disorder:
| Property | Value |
|---|---|
| Cutoff | ≥10 |
| Sensitivity | ~89% |
| Specificity | ~82% |
| Reference | Spitzer, Kroenke, Williams & Löwe, Arch Intern Med 2006 |
A score ≥10 does not diagnose GAD — it identifies patients who need a clinical interview to establish DSM-5-TR criteria (excessive worry, difficulty controlling worry, associated symptoms, ≥6 months duration, functional impairment). Document both the screen result and the interview findings separately.
GAD-7 Beyond GAD — What Else It Detects
The GAD-7 was designed for generalized anxiety but performs well as a broad anxiety screener:
| Condition | GAD-7 performance |
|---|---|
| Generalized anxiety disorder | Primary target — best validated |
| Panic disorder | Elevated scores common; does not distinguish panic from GAD |
| Social anxiety disorder | Elevated scores; screen with dedicated measures for specificity |
| PTSD | Elevated scores reflect hyperarousal/avoidance overlap; use PCL-5 for PTSD screening |
| Any anxiety disorder | GAD-7 ≥10 has good sensitivity for "any anxiety disorder" as a category |
GAD-7 + PHQ-9 — The Standard Pair
GAD-7 and PHQ-9 are almost always administered together because anxiety and depression co-occur at high rates (~60% comorbidity in clinical samples):
| Combined pattern | Interpretation |
|---|---|
| PHQ-9 ≥10, GAD-7 <10 | Depression positive, anxiety negative |
| PHQ-9 <10, GAD-7 ≥10 | Anxiety positive, depression negative |
| Both ≥10 | Comorbid depression + anxiety — common; assess both, consider combined treatment |
| Both <10 | Neither screen positive — routine care |
Administering both takes under 5 minutes total and gives a complete picture of the two most common behavioral health presentations.
Functional Impairment Question (Q8)
The GAD-7 includes an optional 8th question (not scored): "If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?" — rated 0 (not difficult) to 3 (extremely difficult).
| Q8 score | Use |
|---|---|
| 0–1 | Symptoms may not meet functional-impairment criterion |
| 2–3 | Supports clinically significant impairment — relevant for DSM-5-TR criterion F |
Clinical Workflow
| Step | Action |
|---|---|
| 1. Administer | Patient completes GAD-7 (paper, portal, or tablet) — takes ~2 minutes |
| 2. Score | Sum items; apply severity bands |
| 3. Interpret | ≥10 → positive screen; 5–9 → monitor/rescreen; <5 → routine |
| 4. Pair with PHQ-9 | Depression-anxiety comorbidity check |
| 5. Diagnose | Positive screen → clinical interview for DSM-5-TR criteria |
| 6. Track | Repeat GAD-7 every 2–4 weeks during active treatment to measure response |
Scoring Examples
| Scenario | Items pattern | Total | Severity |
|---|---|---|---|
| No symptoms | All 0s | 0 | Minimal |
| Occasional worry | Several 1s | 5–9 | Mild |
| Moderate anxiety | Mix of 1s, 2s, a few 3s | 10–14 | Moderate |
| Severe anxiety | Mostly 2s and 3s | 15–21 | Severe |
GAD-7 vs. GAD-2 — The Ultra-Brief Pre-Screen
The first two items alone form the GAD-2, a 2-item ultra-brief screen:
| GAD-2 score | Interpretation |
|---|---|
| 0–2 | Negative — anxiety unlikely; no further screening needed |
| ≥3 | Positive — administer full GAD-7 |
The GAD-2 exists for time-constrained settings (annual wellness visits, busy intake) — it trades some accuracy for speed, the same way the PHQ-2 does for depression.
Special Populations
| Population | Recommendation |
|---|---|
| Perinatal patients | The EPDS (Edinburgh Postnatal Depression Scale) includes anxiety items and is preferred in pregnancy/postpartum; GAD-7 is acceptable and widely used |
| Older adults | GAD-7 performs well, but somatic items (restlessness, trouble relaxing) can be inflated by medical illness or medication effects — interpret with clinical context |
| Adolescents | GAD-7 is validated down to roughly age 12; pair with clinical interview given developmental expression of anxiety |
| Chronic medical illness | Somatic overlap (fatigue, restlessness) can inflate scores — track item trends rather than totals alone |
| Cultural/linguistic diversity | Use validated translations; pair scores with clinical interview since distress expression varies culturally |
Payer Requirements for Anxiety Screening
| Program | Requirement | GAD-7 role |
|---|---|---|
| Medicare Annual Wellness Visit | Depression screening is required (G0444); anxiety screening supports the visit's behavioral health review | GAD-7 documents the anxiety assessment |
| HEDIS / payer quality programs | Documented screening for behavioral health populations | Scored GAD-7 with severity interpretation |
| CPT 96127 | Staff-administered test administration + scoring, billable | See billing section below |
Automated Scoring in Neuraline
Neuraline's AI Screening module ships with GAD-7 pre-seeded — alongside PHQ-9, Y-BOCS, BDI, HAM-D, MMSE, AUDIT, and CAGE — so scores compute automatically the moment a patient submits:
| Capability | How it works |
|---|---|
| Auto-scoring | Total score, severity band, and trend computed instantly — no hand tallying |
| PHQ-9 pairing | Administer GAD-7 + PHQ-9 together; both scores land on the chart |
| Portal administration | Assign GAD-7 to patients; they complete it before the visit |
| Encounter administration | Administer and score during the visit |
| AI interpretation | Plain-language interpretation, clinical implications, and risk level |
| 3-click AI Charting | The score flows into the encounter note — draft, review, sign in three clicks |
The chart documents the instrument, score, severity, and interpretation automatically — audit-ready for CPT 96127 claims and payer quality reporting.
Billing: CPT 96127
When staff administer and score the GAD-7, the work is billable under CPT 96127 — psychological or neuropsychological test administration with scoring by a practice staff member under physician or qualified healthcare professional supervision, per hour of staff time:
| Rule | Detail |
|---|---|
| Who bills | The supervising physician or qualified healthcare professional |
| Time rule | Per hour of staff time; 16-minute minimum (one unit typically covers a screening session) |
| Frequency | Most payers allow one unit per patient per day |
| Same-day E/M | Generally billable alongside an E/M visit — document the screening separately |
| Documentation | Instrument name, administration date, raw score, severity interpretation, staff time, supervising provider |
| Typical reimbursement | Roughly $1–2 per unit (varies by payer and region) |
Tip: when GAD-7 and PHQ-9 are administered in the same session, document both under the same 96127 unit — the 16-minute minimum covers the combined administration.
Download the Free GAD-7 PDF
Need a printable worksheet? Get the free GAD-7 anxiety screening form — plus PHQ-9, PCL-5, ASRS, C-SSRS, EPDS, and MDQ — in the Screening PDFs Library. All worksheets are free; scoring guides for each instrument are linked there too.
Frequently Asked Questions
Is the GAD-7 a diagnostic test for GAD only?
No — it screens for generalized anxiety disorder but elevated scores also appear in panic disorder, social anxiety disorder, and PTSD. It is best used as a broad anxiety screener plus severity tracker, not a standalone diagnostic tool.
How often should GAD-7 be repeated?
During active treatment, every 2–4 weeks is standard for monitoring response. A drop of ≥4 points is considered a clinically meaningful improvement.
Can GAD-7 be used for billing?
Yes — anxiety screening measures support medical necessity for behavioral health services and are commonly required by payers for anxiety treatment authorization. Document the score, date, and clinical interpretation.
What if GAD-7 is high but PHQ-9 is low?
This pattern suggests anxiety without depression — still warrants clinical evaluation. Anxiety disorders are the most common mental health condition in the US (~19% annual prevalence) and frequently present without comorbid depression.
This guide summarizes GAD-7 scoring for clinical reference. Always verify scoring against the official instrument and your organization's protocols.
Score GAD-7 and PHQ-9 automatically in Neuraline — seeded screening instruments with severity bands and alert thresholds. Explore screening or book a demo.
